Condition
Locoregional Recurrence
Total Trials
5
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (1)
P 3 (1)
Trial Status
Recruiting3
Unknown1
Not Yet Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT05467891Phase 2RecruitingPrimary
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT06452485RecruitingPrimary
Postoperative Re-irradiaTion With and Without HYPERthermia: Toxicity, Quality of Life and Survival in Patients With Locoregional Recurrent Breast Cancer
NCT07190443Phase 3Recruiting
Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)
NCT05988112Not Yet RecruitingPrimary
Locoregional Recurrence of Breast Cancer
NCT04550910Not ApplicableUnknown
RCT Comparing 2 Radiotherapy HypoFractionation Schedules In Breast Cancer Patients
Showing all 5 trials